Negative serology (antibody test) for the following infectious diseases:\r\n* Human immunodeficiency virus (HIV) type  and \r\n* Human T-cell leukemia virus (HTLV) type  and  (mandatory in United States [US] but optional in Canada and Europe)\r\n* Hepatitis B surface antigen\r\n* Hepatitis C antibody
Patient has a positive test for Hepatitis B surface antigen, Hepatitis C antibody, human immunodeficiency virus HIV- or HIV- antibody, or has a history of a positive result for hepatitis C virus (HCV) or HIV
Negative virology/serology for human immunodeficiency virus (HIV)-, HIV-, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) DNA
Seropositive for Human Immunodeficiency Virus (HIV)  or HIV , or positive hepatitis B surface antigen (HBsAg) or hepatitis C antibody
DONOR: HIV negative, hepatitis B virus surface antigen negative, and hepatitis C virus antibody negative
Documented negative human immunodeficiency infection virus (HIV) antigen and antibody, hepatitis B surface antigen, and hepatitis C antibody within  months prior to enrollment; for patient with positive hepatitis C antibody (Ab), negative polymerase chain reaction (PCR) testing must be documented in order to be eligible
Human immunodeficiency virus (HIV)/hepatitis B virus (HBV)/hepatitis C positive (HCV) infection:\r\n* Seropositive for HIV antibody; (patients with HIV are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy in the future should study results indicate effectiveness) \r\n* Seropositive for hepatitis C or positive for hepatitis B surface antigen (HbsAG)
Documented negative human immunodeficiency virus (HIV) antigen and antibody, hepatitis B surface antigen, and hepatitis C antibody within  months prior to enrollment; for patient with positive hepatitis C antibody (Ab), negative PCR testing must be documented in order to be eligible
Known human immunodeficiency virus (HIV), hepatitis C, or hepatitis B positivity (subjects with hepatitis B surface antigen [SAg] or core antibody positivity, who are receiving and responding to antiviral therapy directed at hepatitis B or are negative for hepatitis B virus [HBV] deoxyribonucleic acid [DNA], are allowed)
Documented negative human immunodeficiency virus (HIV) antigen and antibody, hepatitis B surface antigen, and hepatitis C antibody within  months prior to enrollment; for patient with positive hepatitis C antibody (Ab), negative PCR testing must be documented in order to be eligible
Patients known to be human immunodeficiency virus (HIV) positive, hepatitis B or C positive, or both rapid plasma reagin (RPR) and fluorescent treponemal antibody (FTA) positive; (hepatitis B surface or core antibody alone is not indicative of hepatitis B virus [HBV] infection)
DONOR: Infectious disease screening performed within  days prior to stem cell mobilization per federal guidelines and is:\r\n* Seronegative for HIV + antibody (Ab) and/or HIV polymerase chain reaction (PCR), human T-cell leukemia virus (HTLV) I/II Ab, hepatitis B virus surface antigen (HBsAg), hepatitis B virus surface antibody (HBcAb), hepatitis C virus (HCV) Ab\r\n* Negative rapid plasma reagin (RPR) for syphilis
Performance of a donor infectious disease screen panel including cytomegalovirus (CMV) antibody, hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, HIV / antibody, HTLVA / antibody, rapid plasma reagin and Trypanosoma cruzi (T. cruzi) or per current standard institutional donor screen  must be negative for HIV and active hepatitis B
DONOR: Performance of a donor infectious disease screen panel including cytomegalovirus (CMV) antibody, hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, human immunodeficiency virus (HIV) polymerase chain reaction (PCR), HIV  antibody, human T-lymphotropic virus antibody (HTLVA)  antibody, rapid plasma reagin (RPR), treponema and trypanosoma Cruzi (T. Cruzi), plus nucleic acid testing (NAT) testing (hepatitis B virus [HBV], hepatitis C virus [HCV], West Nile virus [WNV], HIV by nucleic acid method); or per current panel  must be negative for HIV and active hepatitis B
Active/chronic hepatitis B infection (based on positive surface antigen [HBsAg]), hepatitis C infection (based on positive antibody [HCV Ab]), or human immunodeficiency virus (HIV- or HIV-, based on positive antibody)
Have active infection with human immunodeficiency virus (HIV) (negative HIV / antibody screen), hepatitis C (negative hepatitis C antibody screen), or hepatitis B (negative hepatitis B surface antigen); any positive serologies for HIV or viral hepatitis should be confirmed with appropriate confirmatory testing before concluding that an active infection is present; subjects with positive hepatitis core antibody are also excluded since the effect of long-term B cell depletion on the risk of hepatitis B reactivation is unknown
Active/chronic hepatitis B infection (based on positive surface antigen [HBsAg]), hepatitis C infection (based on positive antibody [HCV Ab]), or human immunodeficiency virus (HIV- or HIV-, based on positive antibody)
Human immunodeficiency virus (HIV) negative and hepatitis B surface antigen (HBs-Ag) negative
Patients who test positive for human immunodeficiency virus (HIV), hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, human T-lymphotropic virus (HTLV) I or II antibody, or are both rapid plasma reagin (RPR) and fluorescent treponemal antibody (FTA) positive are excluded
DONOR: Donor has undergone serologic testing for transmissible diseases as per blood banking guidelines for organ and tissue donors; tests include but are not limited to: hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core antibody, hepatitis C antibody, Epstein-Barr virus antibody, human immunodeficiency virus (HIV), human T-cell leukemia virus (HTLV) I and II, varicella zoster (herpes zoster), herpes simplex antibody, cytomegalovirus antibodies, syphilis (rapid plasma reagin [RPR] profile) for adolescents and adults, measles for pediatric patients, West Nile virus, Chagas screen, and toxoplasma antibodies
DONOR: Negative testing for relevant communicable diseases\r\n* Testing for infectious disease includes:\r\n** Hepatitis B surface antigen (HBsAg)\r\n** Hepatitis B core antibody (Anti-HBc)\r\n** Hepatitis C antibody (Anti-HCV)\r\n** HIV  &  antibody (Anti-HIV-,  plus O)\r\n** Human T-lymphotropic virus (HTLV) I/II antibody (Anti-HTLV I/II)\r\n** Rapid plasma reagin (RPR) (Syphilis Treponema pallidum [TP])\r\n** Cytomegalovirus (CMV) (Capture CMV)\r\n** Multiplex (MPX) for: HepB (HBV-PCR), HepC (HCV-PCR), HIV (HIV-PCR)\r\n** Nucleic acid testing (NAT) for West Nile Virus (WNV-PCR)\r\n** Trypanosoma cruzi (T. Cruzi) - enzyme immunoassay (EIA) (Chagas)\r\n* Laboratory testing for infectious disease will be performed at the time of initial donor assessment and must be performed within  days of the HSC collection; if multiple collections of HSC occur from the same donor, the infectious disease testing shall be performed within  days prior to each collection
Seropositive for HIV antibodies (HIV and HIV), Hepatitis C antibody (Hep C Ab) or a Hepatitis B carrier (positive for Hepatitis B surface antigen [HBsAg]).
DONOR: Seronegative for human immunodeficiency virus (HIV) antigen (Ag), HIV + antibody (Ab), human T-lymphotropic virus (HTLV) I/II Ab, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) (immunoglobulin [Ig]M and IgG), hepatitis C virus (HCV) Ab, rapid plasma reagin (RPR) for syphilis within  days of apheresis collection
DONOR: Hepatitis A, B and C, HIV  and , human T-lymphotropic virus (HTLV), varicella zoster virus (VZV), Epstein-Barr virus (EBV), herpes simplex virus (HSV), West Nile virus, Syphilis Treponema, T cruzi (Chagas), cytomegalovirus (CMV), and the MPX nucleic acid test (NAT) individual donor testing (IDT) (human immunodeficiency virus [HIV]/hepatitis C virus [HCV]/hepatitis B virus [HBV]) will be tested as per national standard of care guidelines for transplant donors; donors who are HIV positive will be excluded; donors who are positive by serology for Hepatitis B or C are eligible as long as polymerase chain reaction (PCR) for ribonucleic acid (RNA)/deoxyribonucleic acid (DNA) is negative
Known history of seropositive for human immunodeficiency virus (HIV) antibodies (HIV and HIV), hepatitis C antibody (Hep C Ab) or a hepatitis B carrier (positive for hepatitis B surface antigen [HBsAg])
Documented negative human immunodeficiency virus (HIV) antigen and antibody, hepatitis B surface antigen and hepatitis C antibody within  months prior to enrollment; for patients with positive hepatitis C antibody (Ab), negative polymerase chain reaction (PCR) testing must be documented in order to be eligible
DONOR: Donor is to be negative for human immunodeficiency virus (HIV) antigen (Ag), HIV + antibody (Ab), human T-lymphotropic virus (HTLV) I/II Ab, hepatitis B surface antigen (HbsAg), hepatitis B core antibody (HbcAb) (immunoglobulin [Ig]M [combination screening test] and IgG), hepatitis C virus (HCV), and rapid plasma reagin (RPR) for syphilis within  days of apheresis collection; if the only donor is positive for Hepatitis B or C or syphilis, the recipient must be notified - the recipient may proceed if Principal Investigator (PI), recipient and donor agree and there is no alternative related donor
Patients who demonstrate the presence of antibodies to human immunodeficiency virus (HIV) or hepatitis C or presence of hepatitis B surface antigen or other active infectious process that could suppress the immune system and potentially interfere with the development of an immune response to the tumor antigen are NOT eligible for participation
Known human immunodeficiency virus (HIV) seropositive, hepatitis C infection, and/or hepatitis B (except for patients with hepatitis B surface antigen [Sag] or core antibody receiving and responding to antiviral therapy directed at hepatitis B: these patients are allowed)
MATCHED RELATED DONOR: Donors must be HIV negative, hepatitis B surface antigen negative, and hepatitis C antibody negative; this is to prevent the possible transmission of these infections to the recipient
HAPLOIDENTICAL RELATED DONOR: Donors must be HIV negative, hepatitis B surface antigen negative, and hepatitis C antibody negative; this is to prevent the possible transmission of these infections to the recipient
MATCHED RELATED DONOR: Donors must be human immunodeficiency virus (HIV) negative, hepatitis B surface antigen negative, and hepatitis C antibody negative
HAPLOIDENTICAL RELATED DONOR: Donors must be HIV negative, hepatitis B surface antigen negative, and hepatitis C antibody negative
DONOR: Donors must be human immunodeficiency virus (HIV) negative, hepatitis B surface antigen negative, and hepatitis C antibody negative
Documented evidence of negative tests for the presence of hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) and HIV antibodies within the three months preceding study entry; subjects who do not have such evidence must undergo appropriate testing prior to virus administration
Known positive virology/serology for human immunodeficiency virus (HIV)-, HIV-, hepatitis B (surface antigen), or hepatitis C.
Positivity for hepatitis B (defined as HepBs Antigen +), hepatitis C (defined as HepC Antibody +), or HIV; HIV positive patients on antiretroviral therapy will be excluded;
DONORS: Performance of a donor infectious disease screen panel including cytomegalovirus (CMV) antibody, hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, human immunodeficiency virus (HIV) / antibody, human T-cell leukemia-lymphoma virus (HTLV) / antibody, Treponema, and trypanosoma cruzi (T. Cruzi) plus hepatitis B virus (HBV), hepatitis C virus (HCV), West Nile virus (WNV), HIV by nucleic acid testing (NAT); or per current standard institutional donor screen  must be negative for HIV and active hepatitis B
Subject is known to be seropositive for human immunodeficiency virus (HIV), hepatitis B surface antigen, or hepatitis C antibody (unless treated curatively)
Human immunodeficiency virus (HIV) positive or evidence of infection with hepatitis B or C virus, as defined by any of the following criteria (if patients have not previously been tested for the following, these will be conducted during screening):\r\n* HIV antibody positive\r\n* Hepatitis B surface antigen or core antibody positive\r\n* Hepatitis C antibody positive
DONOR: Serologies for human immunodeficiency virus (HIV) antigen (Ag), HIV  and HIV  antibody (Ab), human T-cell lymphotropic virus (HTLV)  and HTLV  Ab, hepatitis B surface antigen (sAg) or polymerase chain reaction (PCR)+, or hepatitis C Ab or PCR+, syphilis (Treponema) screen and HIV  and hepatitis C by NAT (nucleic acid testing) have been collected prior to apheresis
DONOR: Seronegative for human immunodeficiency virus (HIV)- ribonucleic acid (RNA) polymerase chain reaction (PCR), HIV  and HIV  antibody (ab), human T-cell lymphotropic virus type (HTLV)- and HTLV- ab; PCR positive (+) or surface antigen (sAg) hepatitis B; or PCR+ or sAg for hepatitis C; negative for the Treponema palladum antibody syphillis screen; and negative for HIV- and hepatitis C by nucleic acid testing (NAT) within  days of apheresis collection; in the case that Treponema (T) palladum antibody tests are positive, donors must:\r\n* Be evaluated and show no evidence of syphilis infection of any stage by physical exam and history\r\n* Have completed effective antibiotic therapy to treat syphilis\r\n* Have a documented negative non treponemal test (such as rapid plasma reagin [RPR]) or in the case of a positive non treponemal test must be evaluated by an infectious disease expert to evaluate for alternative causes of test positivity and confirm no evidence of active syphilitic disease
Have known seropositivity for human immunodeficiency virus, hepatitis C virus, hepatitis B surface antigen, or syphilis; does not require serologic confirmation as a study procedure
DONOR: Performance of a donor infectious disease screen panel including cytomegalovirus (CMV) antibody, hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, HIV / antibody, HTLVA / antibody, rapid plasma reagin and Trypanosoma cruzi (T. cruzi) or per current University of Minnesota, Fairview Medical Center standard donor screen  must be negative for HIV and active hepatitis B
Patients testing positive for human immunodeficiency virus (HIV) titre, hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, human T-lymphotropic virus (HTLV) I or II antibody, or both rapid plasma reagin (RPR) and fluorescent treponemal antibody (FTA) positive are excluded
Patients testing positive for human immunodeficiency virus (HIV) titre, hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, human T-lymphotropic virus (HTLV) I or II antibody, or both rapid plasma reagin (RPR) and fluorescent treponemal antibody (FTA) positive are excluded
Patients who have human immunodeficiency virus (HIV) or hepatitis C; patients would not be excluded for hepatitis B surface antigen positivity if on lamivudine or entecavir
Patients who have human immunodeficiency virus (HIV) or hepatitis C; patients would not be excluded for hepatitis B surface antigen positivity if on lamivudine
Primary malignancy of the central nervous system or malignancies related to human immunodeficiency virus or solid organ transplant. History of known HIV. History of known Hepatitis B surface antigen or positive Hepatitis C antibody (confirmed by RIBA).
DONOR: Donor has undergone serologic testing for transmissible diseases as per blood banking guidelines for organ and tissue donors; tests include but are not limited to: hepatitis B surface antigen (HepBsAg), hepatitis B surface antibody (HepBsAb), hepatitis B core antibody (HepBcAb), hepatitis C (HepC) antibody, human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV) I and II, varicella zoster virus (VZV), cytomegalovirus (CMV) and Venereal Disease Research Laboratory (VDRL), West Nile virus and Chagas screen; donor must have normal negative test results for HIV, HTLV I and II, and West Nile virus; donor exposure to other viral pathogens will be discussed on a case-by-case basis by the investigators
Participant is known to be seropositive for human immunodeficiency virus (HIV), known to have hepatitis B surface antigen positivity, or history of to have a history of hepatitis C
Negative serology tests for human immunodeficiency virus (HIV) Ab/Ag Combo, and for active hepatitis B or hepatitis C, within  days of first peripheral blood collection for sipuleucel-T
Patients must have negative antibody serology for the human immunodeficiency virus (HIV and ) and hepatitis C virus and negative test for hepatitis B surface antigen
DONOR: Donors must not be seropositive for HIV  and , hepatitis B surface antigen, hepatitis B core antibody, human T-lymphotropic virus (HTLV) antibody, cytomegalovirus (CMV) immunoglobulin (Ig)M, or rapid plasma reagin (RPR) (Treponema)
Negative virology/serology for human immunodeficiency virus (HIV)-, HIV-, hepatitis B (surface antigen), and hepatitis C
DONOR: Donors must be human immunodeficiency virus (HIV) negative, hepatitis B surface antigen negative, and hepatitis C antibody negative
Donor has undergone serologic testing for transmissible diseases as per blood banking guidelines for organ and tissue donors; tests include but are not limited to: hepatitis B surface antigen (HepBsAg), hepatitis B surface antibody (HepBsAb), hepatitis B core antibody (HepBcAb), HepC antibody, human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV) I and II, varicella zoster virus (VZV), cytomegalovirus (CMV) and Venereal Disease Research Laboratory test (VDRL), and West Nile virus; donor must have normal negative test results for HIV, HTLV I and II, and West Nile virus
Positive test result for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab).
Patient has documented evidence of negative tests for the presence of hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV)/ antibodies within the three months preceding study entry; subjects who do not have such evidence must undergo appropriate testing prior to virus administration; HIV-positive patients are ineligible
Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or Human Immunodeficiency Virus (HIV) -, - antibody
Patient has a positive test for Hepatitis B surface antigen, Hepatitis C antibody, human immunodeficiency virus (HIV)-, or HIV- antibody, or has a history of a positive result.
Patient has a positive test for Hepatitis B surface antigen, Hepatitis C antibody, HIV-, or HIV- antibody, or has a history of a positive result.
Known human immunodeficiency virus (HIV) seropositive, hepatitis C infection, and/or hepatitis B (except for patients with hepatitis B surface antigen [SAg] or core antibody receiving and responding to antiviral therapy directed at hepatitis B: these patients are allowed)
Seropositive for HIV antibodies (HIV and HIV), Hepatitis C antibody (Hep C Ab) or a Hepatitis B carrier (positive for Hepatitis B surface antigen [HBsAg]).
Known human immunodeficiency (HIV) seropositive, hepatitis C infection, and/or hepatitis B (except for patients with hepatitis B surface antigen [SAg] or core antibody receiving and responding to antiviral therapy directed at hepatitis B: these patients are allowed).
Known positivity for hepatitis B surface antigen (sAg), hepatitis C antibody, or human immunodeficiency virus (HIV) antibody
DONOR: Serologies for human immunodeficiency virus (HIV) antigen (Ag), HIV  and HIV  antibody (Ab), human T-lymphotropic virus type I (HTLV ) and HTLV  Ab, hepatitis B surface antigen (sAg) or polymerase chain reaction positive (PCR+), or hepatitis C Ab or PCR+, syphilis (Treponema) screen and HIV  and hepatitis C by nucleic acid testing (NAT) have been collected prior to apheresis
DONOR: All donors will be screened for the following:\r\n* Human immunodeficiency virus (HIV) I\r\n* HIV II\r\n* Hepatitis surface antigen (HbsAg)\r\n* Hepatitis B core antibody (HBc)\r\n* Hepatitis C virus (HCV)\r\n* Cytomegalovirus (CMV)\r\n* Syphilis\r\n* Human T-lymphotropic virus (HTLV I/II)\r\n* Epstein-Barr virus (EBV) and adenovirus immunoglobulin G (IgG) when feasible
History of chronic hepatitis, Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except participants with liver cancer) or Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS)
